376 related articles for article (PubMed ID: 16316392)
1. Antibody levels and protection to canine parvovirus type 2.
Elia G; Cavalli A; Cirone F; Lorusso E; Camero M; Buonavoglia D; Tempesta M
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):320-2. PubMed ID: 16316392
[TBL] [Abstract][Full Text] [Related]
2. Maternally-derived antibodies in pups and protection from canine parvovirus infection.
Decaro N; Campolo M; Desario C; Elia G; Martella V; Lorusso E; Buonavoglia C
Biologicals; 2005 Dec; 33(4):261-7. PubMed ID: 16168665
[TBL] [Abstract][Full Text] [Related]
3. Immunization of pups with maternally derived antibodies to canine parvovirus (CPV) using a modified-live variant (CPV-2b).
Pratelli A; Cavalli A; Normanno G; De Palma MG; Pastorelli G; Martella V; Buonavoglia C
J Vet Med B Infect Dis Vet Public Health; 2000 May; 47(4):273-6. PubMed ID: 10861195
[TBL] [Abstract][Full Text] [Related]
4. Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection.
Larson LJ; Schultz RD
Am J Vet Res; 1997 Apr; 58(4):360-3. PubMed ID: 9099379
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CPV-2b and CPV-2c.
Siedek EM; Schmidt H; Sture GH; Raue R
Berl Munch Tierarztl Wochenschr; 2011; 124(1-2):58-64. PubMed ID: 21306055
[TBL] [Abstract][Full Text] [Related]
6. Intranasal vaccination of pups in the presence of maternally derived antibodies to canine parvovirus (CPV). Evaluation of minimal immunizing dose.
Buonavoglia C; Cavalli A; Tempesta M; Voight V; Buonavoglia D; Corrente M; Sagazio P
New Microbiol; 1995 Oct; 18(4):371-5. PubMed ID: 8590389
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of two canine parvovirus vaccines for inducing seroconversion in Rottweiler and Doberman pinscher pups with various levels of maternally derived antibodies.
Coyne MJ
Vet Ther; 2000; 1(1):35-42. PubMed ID: 19757563
[TBL] [Abstract][Full Text] [Related]
8. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant?
Larson LJ; Schultz RD
Vet Ther; 2008; 9(2):94-101. PubMed ID: 18597247
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c.
Wilson S; Illambas J; Siedek E; Stirling C; Thomas A; Plevová E; Sture G; Salt J
Vaccine; 2014 Sep; 32(42):5420-4. PubMed ID: 25148778
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain.
Pratelli A; Altamura M; Buonavoglia D; Pepe M; Tafaro A; Lembo A; Cirone F; Tempesta M; Jirillo E; Buonavoglia C
Immunopharmacol Immunotoxicol; 2000 Aug; 22(3):451-64. PubMed ID: 10946825
[TBL] [Abstract][Full Text] [Related]
11. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus.
Spibey N; Greenwood NM; Sutton D; Chalmers WS; Tarpey I
Vet Microbiol; 2008 Apr; 128(1-2):48-55. PubMed ID: 18006253
[TBL] [Abstract][Full Text] [Related]
12. Evolution of canine parvovirus--a need for new vaccines?
Truyen U
Vet Microbiol; 2006 Oct; 117(1):9-13. PubMed ID: 16765539
[TBL] [Abstract][Full Text] [Related]
13. Response of puppies to canine-origin parvovirus vaccines.
Carmichael LE; Pollock RV; Joubert JC
Mod Vet Pract; 1984 Feb; 65(2):99-102. PubMed ID: 6328258
[TBL] [Abstract][Full Text] [Related]
14. Intranasal vaccination of pups with maternally derived antibodies with a modified live canine parvovirus.
Buonavoglia C; Cavalli A; Gravino E; Voigt V; Buonavoglia D; de Caprariis D
Zentralbl Veterinarmed B; 1994 Mar; 41(1):3-8. PubMed ID: 7941844
[TBL] [Abstract][Full Text] [Related]
15. Three-year serologic immunity against canine parvovirus type 2 and canine adenovirus type 2 in dogs vaccinated with a canine combination vaccine.
Larson LJ; Schultz RD
Vet Ther; 2007; 8(4):305-10. PubMed ID: 18183549
[TBL] [Abstract][Full Text] [Related]
16. Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus.
Gore TC; Lakshmanan N; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
Vet Ther; 2005; 6(1):5-14. PubMed ID: 15906266
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a low-passage, high-titer modified live canine parvovirus vaccine in pups with maternally derived antibodies.
Hoare CM; DeBouck P; Wiseman A
Vaccine; 1997 Feb; 15(3):273-5. PubMed ID: 9139485
[TBL] [Abstract][Full Text] [Related]
18. Faecal shedding of canine parvovirus after modified-live vaccination in healthy adult dogs.
Freisl M; Speck S; Truyen U; Reese S; Proksch AL; Hartmann K
Vet J; 2017 Jan; 219():15-21. PubMed ID: 28093104
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of vaccination at 4 and 6 weeks in the control of canine parvovirus.
De Cramer KG; Stylianides E; van Vuuren M
Vet Microbiol; 2011 Apr; 149(1-2):126-32. PubMed ID: 21111542
[TBL] [Abstract][Full Text] [Related]
20. Antibodies to parvovirus, distemper virus and adenovirus conferred to household dogs using commercial combination vaccines containing Leptospira bacterin.
Taguchi M; Namikawa K; Maruo T; Lynch J; Sahara H
Vet Rec; 2010 Dec; 167(24):931-4. PubMed ID: 21262693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
